~~<i id='4857AFA90E'><strike id='4857AFA90E'><tt id='4857AFA90E'><pre id='4857AFA90E'></pre></tt></strike></i>~~

Home» comprehensive» hotspot

hotspot

author：explore 2025-10-01 20:45:25 Page View：912

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Spinal cord stimulation reduces pain in amputees, study finds
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

focus

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

SusanGalbraith,AstraZeneca’sheadofcancerresearchanddevelopment,speaksataSTATeventin2023.MarieMillerf

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

Ultragenyx gene therapy for rare liver ailment succeeds in late

JonathanWiggs/GlobeStaffUltragenyxsaidThursdayafternoonthatitsgenetherapyforarareliverailment,glycog